Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.

@article{Schmieder2009LongtermAE,
  title={Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.},
  author={Roland E Schmieder and Thomas Philipp and Javier Guerediaga and Manuel Gorostidi and Beverly A. Smith and Nicole Weissbach and Mojdeh Maboudian and Jaco Botha and H. E. van Ingen},
  journal={Circulation},
  year={2009},
  volume={119 3},
  pages={417-25}
}
BACKGROUND Diuretics are recommended as first-line agents for the treatment of hypertension. This randomized, double-blind, multicenter study assessed the long-term efficacy and safety of the direct renin inhibitor aliskiren in comparison with the diuretic hydrochlorothiazide in patients with essential hypertension. METHODS AND RESULTS After a 2- to 4-week placebo run-in, 1124 patients (mean sitting diastolic blood pressure [BP] 95 to 109 mm Hg) were randomized to aliskiren 150 mg (n=459… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 56 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 14 references

Aliskiren as add-on to amlodipine provides significant additional blood pressure lowering without increased oedema associated with doubling the amlodipine dose

MA Munger, W Drummond, +3 authors DL. Keefe
Eur Heart J. 2006;27 (suppl):117. Abstract • 2009

Similar Papers

Loading similar papers…